Biotricity, Inc. - Condensed Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash flow from operating activities:
Net loss	$ (3,758,212)	$ (3,387,055)
Adjustments to reconcile net loss to net cash used in operations
Stock based compensation	442,155	196,142
Issuance of shares for services	419,217	443,677
Issuance of warrants for services, at fair value	174,976
Accretion expense	879,416	594,083
Change in fair value of derivative liabilities	20,588	589,100
Fair value of warrants issued
Changes in operating assets and liabilities:
Harmonized sales tax recoverable	(19,602)	13,898
Deposits and other receivables	7,983	30,763
Accounts payable and accrued liabilities	(374,650)	305,865
Net Cash used in operating activities	(2,208,129)	(1,213,482)
Cash flows from financing activities:
Issuance of shares, net	2,340,409
Proceeds from exercise of warrants		105,500
Issuance of convertible debentures, net		1,349,200
Due to shareholders		(50,724)
Net Cash provided by financing activities	2,340,409	1,403,976
Effect of foreign currency translation	50,001	(220,352)
Net increase in cash during the period	132,280	190,494
Cash, beginning of period	424,868	53,643
Cash, end of period	$ 607,149	$ 23,783